{"id":"W4319660667","doi":"10.1016/s0140-6736(22)02574-0","title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; EMD Serono; Ono Pharmaceutical; Eisai; Incyte; Exelixis; Memorial Sloan-Kettering Cancer Center; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Ipilimumab; Nephrectomy; Adjuvant; Placebo; Internal medicine; Urology; Clinical trial; Carcinoma; Oncology; Surgery; Gastroenterology; Immunotherapy; Kidney; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009555044,0.0004846941,0.00136095,0.0001932165,0.0001986491,0.000086215,0.000388217,0.0001846476,0.0002959933],"category_scores_gemma":[0.0000928431,0.0003179021,0.000559199,0.0004697463,0.0001545007,0.00009256071,0.0001256828,0.0003722625,0.0004068715],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004147915,"about_ca_system_score_gemma":0.0003976926,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001295623,"about_ca_topic_score_gemma":0.00005377041,"domain_scores_codex":[0.9969617,0.0001859786,0.0006292333,0.0006334913,0.0005978272,0.0009917633],"domain_scores_gemma":[0.9974427,0.0006739052,0.0002218058,0.001230833,0.0001361258,0.0002946285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9714437,0.0002919518,0.00004549989,0.0002341171,0.0002615879,0.0004069942,0.0007696279,0.00005915207,0.001687448,0.00001958051,0.02376031,0.001019996],"study_design_scores_gemma":[0.9562244,0.003575937,0.0001553523,0.00007228278,0.001073121,0.00003294601,0.0001694459,0.002876336,0.01742558,0.00005939824,0.01799543,0.0003397889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831378,0.0008439632,0.0001745987,0.001790482,0.001102187,0.008636735,0.0001797079,0.0003142802,0.003820237],"genre_scores_gemma":[0.9866189,0.0000700174,0.0003593617,0.0003262805,0.003311371,0.004074875,0.0003779585,0.000110458,0.004750717],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01573813,"threshold_uncertainty_score":0.9999273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09256596557415632,"score_gpt":0.3391126640744914,"score_spread":0.2465466985003351,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}